One can think about the 'burden' of a disease (BoD) in two ways:
The first is obvious, i.e. the consequences of the disease on the individual who suffers from it. We already work on symptoms, signs, disability and impairment of qualityof life (QoL) related to the evolution and complications of chronic venous disorders (CVDs). The literature provides information on these effects, and their description is essentially clear and satisfactory. However, their point of prevalence remains fuzzy because of the lack of epidemiological studies, and because of the differences in disease management or data management between countries.
The second, which is less obvious, more specific and certainly unknown to most physicians, is the socioeconomic appraisal of the consequences of a disease in a population. This is the main subject of this editorial; we will call it the Burden of CVD (BoV). The first Global Burden of Diseases campaign began in 1990 and was commissioned by the World Bank. Another campaign, sponsored by the World Health Organization (WHO) and several other institutions and universities, commenced in 2005. 1 The burden of many diseases, not all potentially lethal, has been evaluated from malaria to diabetes.
The WHO has provided the following definition: 'The WHO global burden of disease (GBD) measures burden of disease using the disability-adjusted life year (DALY). This time-based measure combines years of life lost due to premature mortality and years of life lost due to time lived in states of less than full health. The DALY metric was developed in the original GBD 1990 study to assess the burden of disease consistently across diseases, risk factors and regions'. 2 The formula DALY ¼ YLL + YLD (years of life lost + years of life lost due to disability) may look cryptic but deserves some attention. 3,4 Another measurement, Quality Adjusted Life Years (QALYs) 5,6 may also be used.
The WHO classification of diseases (ICD-10) mentions CVDs in chapters I83, I86.2, I86.3, I87. 7 However, CVD has not been well described or appraised, although it is of utmost importance to us.
What is interesting and important in evaluating the BoV?
The BoV, especially if evaluated through DALYs and QALYs, allows descriptions and comparisons between populations, aetiologies and groups. It also allows cost-effectiveness of health-care technologies assessment. To our knowledge, even if several teams have been working on CVDs with these kinds of tools as part of the GBD project, no presentation has appeared in our meetings and few papers have appeared in journals. 8, 9 What are the intrinsic difficulties of BoD appraisal?
Since CVDs are (fortunately) very seldom lethal, appraisal through YLL is impossible. Mutilations (leg ulcers) and amputations are more frequent, 10 but are probably not always applicable in Western countries since the incidence of chronic venous insufficiency (CVI) ulcers is probably below 2% in general, and below 1% in some countries. The BoD also depends on signs, symptoms and consequences on everyday life. To some extent, generic (EuroQol EQ5D, SF 36 or SF 12, etc.) and specific (CIVIQ, AVVQ, SQOR-V, etc.) QoL scales can be used, but they assess the QoL instead of the burden of the disease, and logically, a different approach must be taken when constructing an auto-questionnaire for assessing the specific personal burden of a chronic venous patient. 11 Finally, socioeconomic data must be taken into account such as the number of days off work, number of days in the hospital, cost of drugs and stockings, cost of surgical procedures, etc.
What do we need to know?
As explained in the GBD document (see 'operations manual'), 1 the main steps of evaluation of the specific BoV will require the following: disease and risk factor epidemiological review, mortality estimation (limited in the case of CVDs), cause of death estimation (same observation), disability weights measurement, comparative risk assessment, and years lived with disability (YLD) estimation. It will be necessary to compute DALYs and QALYs in the different groups of patients and to describe the natural history of treated and untreated CVDs.
What do we need to do?
The Alliance against the Burden of chronic Venous disorders (AVB) task force has recently met. Its goals are to publish a complete and comprehensive consensus document on this topic. This document should have enough relevance to be endorsed by the WHO, and serve as a basis for further discussion about CVDs with national and local authorities. It will demonstrate the severe consequences of these disorders, which have not been well appreciated outside our specialty.
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